Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion, adding late‑stage eye drug

Johnson & Johnson announced a definitive agreement to buy Ollin Biosciences for $2.2 billion in cash, with up to $1.125 billion in regulatory and commercial milestones. The acquisition brings Ollin’s Phase 3 bispecific antibody OLN324 for retinal diseases into J&J’s pipeline. Blackstone Life Sciences will provide $750 million to fund the Phase 3 program, contingent on the deal closing. The transaction is expected to close by the end of 2026, subject to regulatory approvals.

The deal expands J&J’s ophthalmology portfolio and positions it to compete with Roche’s Vabysmo (the company says the acquisition adds a potentially best‑in‑class vision‑loss drug). Blackstone’s funding reduces the cash required from J&J for the late‑stage trial (the funding agreement is described in the press release).

  • 1J&J will pay $2.2 billion upfront for Ollin Biosciences.
  • 2The agreement includes up to $1.125 billion in additional milestone payments.
  • 3Blackstone Life Sciences will provide $750 million to fund Phase 3 development of OLN324.
  • 4The acquisition is expected to close before the end of 2026, pending regulatory approvals.
  • Premarket share rise reported as 1.01% versus 1.43%.

Sources